Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: US prospects for Sarepta’s DMD gene therapy; looking at price increases in the US; Eisai plans US CMS coverage for lecanemab; vaccine impact as China rolls back COVID zero policies; and ex-Novo Nordisk CEO Mads Øvlisen shares his career and life lessons.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 9 December 2022, including: US prospects for Sarepta Therapeutics, Inc.’s DMD gene therapy; looking at price increases in the US; Eisai Co., Ltd. plans US CMS coverage for lecanemab; vaccine impact as China rolls back COVID zero policies; and ex-Novo Nordisk A/S CEO Mads Øvlisen shares his career and life lessons.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "A Duchenne Breakthrough Awaits In 2023 - But Risks Remain For Sarepta And US FDA" - Scrip, 6 Dec, 2022.)
(Also see "Drugs From Bausch, J&J And Amgen Top ICER's Unsupported Price Increase List" - Scrip, 6 Dec, 2022.)
(Also see "Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab" - Scrip, 2 Dec, 2022.)
(Also see "China Winds Down 'COVID Zero' But Vaccine Fatigue, Other Worries Linger" - Scrip, 6 Dec, 2022.)
(Also see "Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR" - Scrip, 6 Dec, 2022.)